BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16397021)

  • 1. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
    Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
    Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.
    King JW; Thomas S; Corsi F; Gao L; Dina R; Gillmore R; Pigott K; Kaisary A; Stauss HJ; Waxman J
    Clin Cancer Res; 2009 Feb; 15(4):1145-54. PubMed ID: 19228720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
    J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.
    Savage P; Gao L; Vento K; Cowburn P; Man S; Steven N; Ogg G; McMichael A; Epenetos A; Goulmy E; Stauss HJ
    Blood; 2004 Jun; 103(12):4613-5. PubMed ID: 14988155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
    Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
    Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ
    Blood; 2002 Nov; 100(10):3835-7. PubMed ID: 12411326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
    Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
    Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
    Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
    Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
    Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
    Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
    Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.